Literature DB >> 8627763

High-dose ocular infection with a herpes simplex virus type 1 ICP34.5 deletion mutant produces no corneal disease or neurovirulence yet results in wild-type levels of spontaneous reactivation.

G C Perng1, H Ghiasi, S M Slanina, A B Nesburn, S L Wechsler.   

Abstract

We report here that in the rabbit ocular model of herpes simplex virus type 1 (HSV-1) latency, spontaneous reactivation of the HSV-1 ICP34.5 deletion mutant d34.5 increased significantly in response to increasing infectious doses. At the highest infectious dose of d34.5, the spontaneous reactivation rate was indistinguishable from that of wild-type virus (average spontaneous reactivation rates for d34.5, 0.3 to 1.4% at 2 x 10(5) PFU per eye, 3.4% at 2 x 10(6) PFU per eye, and 6.3 to 11.5% at 1 x 10(8) PFU per eye; average spontaneous reactivation rates for marker-rescued virus, 7.7 to 19.6% at 2 x 10(5) PFU per eye). The percentage of latency-associated transcript (LAT) RNA-positive neurons in sections from trigeminal ganglia (TG) of rabbits latently infected with d34.5 demonstrated a similar dose-response effect as estimated by in situ hybridization (0.05% LAT RNA-positive neurons at 2 x 10(5) PFU per eye and 0.1% LAT RNA-positive neurons at 1 x 10(8) PFU per eye; P = 0.002). In contrast, even at the highest infectious dose (1 x 10(8) PFU per eye), d34.5 was less virulent (23 of 23 survivors) than the normal infectious dose (2 x 10(5) PFU per eye) of marker-rescued virus (14 of 27 survivors; P < 0.0001). In addition, at 1 x 10(8) PFU per eye, d34.5 produced virtually no corneal disease, compared with the production of severe corneal disease by 2 x 10(5) PFU of marker-rescued virus per eye (P < 0.0001). Thus, at increasing infectious doses of d34.5, both spontaneous reactivation and the percentage of neurons expressing LAT appeared to increase, without a corresponding increase in virulence. These results strongly suggest that (i) the phenotypes of neurovirulence and spontaneous reactivation are separable, (ii) the phenotypes of corneal disease and spontaneous reactivation are separable, and (iii) the decreased rate of spontaneous reactivation previously reported for d34.5 (G. C. Perng, R. L. Thompson, N. M. Sawtell, W. E. Taylor, S. M. Slanina, H. Ghiasi, R. Kaiwar, A. B. Nesburn, and S. L. Wechsler, J. Virol. 69:3033-3041, 1995) is at least partially due to a reduced rate of establishing latency.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627763      PMCID: PMC190146     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1.

Authors:  D L Rock; A B Nesburn; H Ghiasi; J Ong; T L Lewis; J R Lokensgard; S L Wechsler
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

2.  Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants.

Authors:  J P Katz; E T Bodin; D M Coen
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

3.  Deletion mutants in the gene encoding the herpes simplex virus type 1 immediate-early protein ICP0 exhibit impaired growth in cell culture.

Authors:  W R Sacks; P A Schaffer
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

4.  Adenine arabinoside effect on experimental idoxuridine-resistant herpes simplex infection.

Authors:  A B Nesburn; C Robinson; R Dickinson
Journal:  Invest Ophthalmol       Date:  1974-04

5.  Expression of a herpes simplex virus 1 open reading frame antisense to the gamma(1)34.5 gene and transcribed by an RNA 3' coterminal with the unspliced latency-associated transcript.

Authors:  M Lagunoff; B Roizman
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

6.  Fine mapping of the major latency-related RNA of herpes simplex virus type 1 in humans.

Authors:  S L Wechsler; A B Nesburn; R Watson; S Slanina; H Ghiasi
Journal:  J Gen Virol       Date:  1988-12       Impact factor: 3.891

7.  Fine mapping of the latency-related gene of herpes simplex virus type 1: alternative splicing produces distinct latency-related RNAs containing open reading frames.

Authors:  S L Wechsler; A B Nesburn; R Watson; S M Slanina; H Ghiasi
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

8.  The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency.

Authors:  G C Perng; E C Dunkel; P A Geary; S M Slanina; H Ghiasi; R Kaiwar; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  An avirulent ICP34.5 deletion mutant of herpes simplex virus type 1 is capable of in vivo spontaneous reactivation.

Authors:  G C Perng; R L Thompson; N M Sawtell; W E Taylor; S M Slanina; H Ghiasi; R Kaiwar; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  The region of the herpes simplex virus type 1 LAT gene that is colinear with the ICP34.5 gene is not involved in spontaneous reactivation.

Authors:  G C Perng; K Chokephaibulkit; R L Thompson; N M Sawtell; S M Slanina; H Ghiasi; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

View more
  23 in total

1.  Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene.

Authors:  D A Leib; M A Machalek; B R Williams; R H Silverman; H W Virgin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

2.  Failure of thymidine kinase-negative herpes simplex virus to reactivate from latency following efficient establishment.

Authors:  Shih-Heng Chen; Angela Pearson; Donald M Coen; Shun-Hua Chen
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

Review 3.  Peculiarities of herpes simplex virus (HSV) transcription: an overview.

Authors:  Július Rajcáni; Vojvodová Andrea; Rezuchová Ingeborg
Journal:  Virus Genes       Date:  2004-04       Impact factor: 2.332

4.  A herpes simplex virus type 1 mutant disrupted for microRNA H2 with increased neurovirulence and rate of reactivation.

Authors:  Xianzhi Jiang; Don Brown; Nelson Osorio; Chinhui Hsiang; Lily Li; Lucas Chan; Lbachir BenMohamed; Steven L Wechsler
Journal:  J Neurovirol       Date:  2015-02-03       Impact factor: 2.643

5.  A virus with a mutation in the ICP4-binding site in the L/ST promoter of herpes simplex virus type 1, but not a virus with a mutation in open reading frame P, exhibits cell-type-specific expression of gamma(1)34.5 transcripts and latency-associated transcripts.

Authors:  L Y Lee; P A Schaffer
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 6.  Experimental investigation of herpes simplex virus latency.

Authors:  E K Wagner; D C Bloom
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

7.  The latency-associated transcript gene enhances establishment of herpes simplex virus type 1 latency in rabbits.

Authors:  G C Perng; S M Slanina; A Yukht; H Ghiasi; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

8.  Role of Herpes Simplex Virus 1 γ34.5 in the Regulation of IRF3 Signaling.

Authors:  Richard Manivanh; Jesse Mehrbach; David M Knipe; David A Leib
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

9.  Cellular FLIP can substitute for the herpes simplex virus type 1 latency-associated transcript gene to support a wild-type virus reactivation phenotype in mice.

Authors:  Ling Jin; Dale Carpenter; Megan Moerdyk-Schauwecker; Adam L Vanarsdall; Nelson Osorio; Chinhui Hsiang; Clinton Jones; Steven L Wechsler
Journal:  J Neurovirol       Date:  2008-11-12       Impact factor: 2.643

10.  A herpes simplex virus type 1 latency-associated transcript mutant with increased virulence and reduced spontaneous reactivation.

Authors:  G C Perng; S M Slanina; A Yukht; B S Drolet; W Keleher; H Ghiasi; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.